期刊文献+

负载紫杉醇双配体纳米药物输送系统的体外生物性能评价 被引量:2

In vitro Biological Activities of Paclitaxel Nanoparticles with Dual Ligands
下载PDF
导出
摘要 目的体外评价带有叶酸和穿膜肽双配体的、负载紫杉醇纳米药物输送系统的生物性能。方法分别用H-F-P NPs、H-Tat-P NPs及H-F-Tat-P NPs孵育细胞,利用流式细胞仪定量评价细胞对带有不同配体纳米药物输送系统的摄取量。再用H-F-Tat-P NPs孵育细胞,利用激光共聚焦显微镜定性评价不同细胞对H-F-Tat-P NPs的摄取量。结果叶酸受体阳性表达的MDA-MB-231细胞摄取H-F-Tat-P NPs的量明显多于H-F-P NPs及H-Tat-P NPs。叶酸受体阴性表达的A549细胞摄取H-F-Tat-P NPs与H-Tat-P NPs的量多于H-F-P NPs。结论叶酸的靶向作用与穿膜肽的穿膜作用能够协同提高药物在靶细胞的聚集,进一步增强药物输送系统的治疗作用,为开发新型、高效药物输送系统提供基础。 Objective To evaluate in vitro biological activities of paclitaxel nanoparticles with dual ligands. Methods The cells were incubated with H-F-P NPs,H-Tat-P NPs,or H-F-Tat-P NPs,and then evaluated by using flow cytometry.Then the cells were incubated with H-F-Tat-P NPs,and evaluated by using confocal laser scanning microscopy. Results Quantitative analysis of cellular uptake of NPs by flow cytometry showed the extend of celluar uptake for A549 cell lines was:H-F-Tat-P NPs H-Tat-P NPs H-F-P NPs. For MDA-MB-231 cells: H-F-Tat-P NPs H-F-P NPs H-Tat-P NPs. Qualitative analysis of cellular uptake of H-F-Tat-P NPs by confocal laser scanning microscopy showed the fluorescent signal of NPs in MDA-MB-231 cells was higher than that of A549 cells under the same conditions. Conclusion The strategy on nanomedicine with dual ligands can enhance the cellular uptake of drug thereby improve its chemotherapeutic efficiency. The nanoparticle system could be used as a promising cancer cell specific delivery system for further investigation.
出处 《中南医学科学杂志》 CAS 2015年第5期520-523,共4页 Medical Science Journal of Central South China
关键词 紫杉醇 穿膜肽 叶酸 纳米药物输送系统 folate tat paclitaxel nanoparticle system
  • 相关文献

参考文献9

  • 1Dietz GP,Bahr M.Delivery of bioaetive molecules into the cell:the Trojan horse approach[J].Mol Cell Neurosci,2004,27(2):85-131.
  • 2Cheng CJ,Saltzman WM.Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides[J].Biomaterials,2011,32:6194-6203.
  • 3Zhao P,Wang H,Yu M,et al.Paclitaxel-loaded,folicacid-targeted and TAT-peptide-conjugated polymeric liposomes:in vitro and in vivo evaluation[J].PharmRes,2010,27(9):1914-1926.
  • 4Steichen SD,Caldorera-Moore M,Peppas NA.A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics[J].Eur J Pharm Sci,2012,48(3):416-427.
  • 5Ross JF,Chaudhuri PK,Ratnam M.Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines[J].Physiologic and Clinical Implications,1994,73(9):2432-2443.
  • 6Ak G,Sanlter SH.Synthesis of folate receptor-targeted and Doxorubicin-coupled chemotherapeutic nanoconjugate and research into its medical applications[J].Prep Biochem Biotechnol,2012,42(6):551-563.
  • 7Dhawan D,Ramos-Vara JA,Naughton JF,et al.Targeting folate receptors to treat invasive urinary bladder cancer[J].Cancer Res,2013,73(2):875-884.
  • 8Wang Y,Newell BB,Irudayaraj J.Folic acid protected silver nanocarriers for targeted drug delivery[J].J Biomed Nanotechnol,2012,8(5):751-759.
  • 9张霞,王冬晓,李颖嘉,王莺.负载紫杉醇的双配体纳米药物输送系统的制备[J].数理医药学杂志,2013,26(4):450-453. 被引量:3

二级参考文献10

  • 1Steichen S D, Caldorera-Moore M, Peppas N A. A review of cur- rent nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci, 2012, 48(3) : 416-427.
  • 2RossJ F, Chaudhuri P K, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications . Cancer, 1994, 73 (9): 2432-2443.
  • 3Campbell I G, Jones T A, Foulkes W D, Trowsdale J. Folate- binding protein is a marker for ovarian cancer. Cancer Res, 1991, 51(19): 5329-5338.
  • 4Ak G, Sanlter S H. Synthesis of folate receptor-targeted and Doxorubicin-coupled chemotherapeutic nanoconjugate and research into its medical applications. Prep Biochem Biotechnol, 2012, 42 (6) : 551-563.
  • 5Dhawan D, Ramos-Vara J A, Naughton J F, et al. Targeting fo- late receptors to treat invasive urinary bladder cancer. Cancer Res, 2013, 73(2):875-884.
  • 6Wang Y, Newell B B, Irudayaraj J. Folic acid protected silver nanocarriers for targeted drug delivery . J Biomed Nanotechnol, 2012, 8(5): 751-759.
  • 7Dietz G P, Bahr M. Delivery of bioaetive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci, 2004, 27 (2): 85 -131.
  • 8Cheng C J, Saltzman W M. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrat- ing peptides. Biomaterials, 2011, 32: 6194-6203.
  • 9Zhao P, Wang H, Yu M, et al. Paclitaxel-loaded, folic-acid-targe- ted and TAT-peptide-conjugated polymeric liposomes: in vitro and in vivo evaluation. Pharm Res, 2010, 27(9): 1914-1926.
  • 10Wang Y, Wang Y, Xiang J, et al. Target-specific cellular uptake of taxol-loaded heparin-PEG-folate nanoparticles . Biomacromolecules, 2010, 11(12) :3531-3538.

共引文献2

同被引文献11

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部